Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918

This article has now been updated. Please use the final version.

Successful and Safe Reinstitution of Chemotherapy for Pancreatic Cancer after COVID-19
Kazumasa NagaiKatsuya KitamuraYuji HiraiDaisuke NutaharaHironori NakamuraJunichi TairaYubu MatsueMasakazu AbeMiho KikuchiTakao Itoi
Author information
JOURNAL OPEN ACCESS Advance online publication

Article ID: 6294-20

Details
Abstract

Cancer patients are regarded as highly vulnerable to SARS-CoV-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after COVID-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.

Content from these authors
© 2021 by The Japanese Society of Internal Medicine
feedback
Top